Log in

OTCMKTS:EMBI - OTCMKTS:EMBI Stock Price, Forecast & News

+0.02 (+25.67 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
Now: $0.10
50-Day Range
MA: $0.16
52-Week Range
Now: $0.10
Volume712,621 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111 for the treatment of glaucoma. Its products pipeline also comprise NB2222 for the treatment of dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3000 for the treatment of methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is headquartered in Long Beach, California.

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:EMBI



Sales & Book Value

Annual SalesN/A



Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive EMBI News and Ratings via Email

Sign-up to receive the latest news and ratings for EMBI and its competitors with MarketBeat's FREE daily newsletter.

OTCMKTS:EMBI (OTCMKTS:EMBI) Frequently Asked Questions

What is OTCMKTS:EMBI's stock symbol?

OTCMKTS:EMBI trades on the OTCMKTS under the ticker symbol "EMBI."

When is OTCMKTS:EMBI's next earnings date?

OTCMKTS:EMBI is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for OTCMKTS:EMBI.

Has OTCMKTS:EMBI been receiving favorable news coverage?

News articles about EMBI stock have trended negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OTCMKTS:EMBI earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for OTCMKTS:EMBI.

What other stocks do shareholders of OTCMKTS:EMBI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OTCMKTS:EMBI investors own include Autodesk (ADSK), BioLife Solutions (BLFS), Cognex (CGNX), NeoGenomics (NEO), Proofpoint (PFPT), Elanco Animal Health (ELAN), Palo Alto Networks (PANW), Panasonic (PCRFY), Arena Pharmaceuticals (ARNA) and Amyris (AMRS).

How do I buy shares of OTCMKTS:EMBI?

Shares of EMBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OTCMKTS:EMBI's stock price today?

One share of EMBI stock can currently be purchased for approximately $0.10.

MarketBeat Community Rating for OTCMKTS:EMBI (OTCMKTS EMBI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  16
MarketBeat's community ratings are surveys of what our community members think about OTCMKTS:EMBI and other stocks. Vote "Outperform" if you believe EMBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EMBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel